{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:13:04Z","timestamp":1789693984713,"version":"4.0.1"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016610","name":"Andrew McDonough B+ Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejca.2025.115230","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T12:16:03Z","timestamp":1736770563000},"page":"115230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration"],"prefix":"10.1016","volume":"217","author":[{"given":"Andrew DJ","family":"Pearson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariella G.","family":"Filbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Grill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Drezner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Dun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua E.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ely","family":"Benaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie","family":"Buenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"de Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Desserich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Friend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Glade Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Hargrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Kholmanskikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Kieran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Knoderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Koschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Ligas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Lipsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Ludwinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynley","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"McDonough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian G.","family":"McNicholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mirsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Monje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Nysom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Pappo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rosenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Scobie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Slaughter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Souweidane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Straathof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Zamoryakhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Karres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Vassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115230_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2019.01.013","article-title":"ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children","volume":"110","author":"Pearson","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115230_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2019.12.029","article-title":"ACCELERATE and European Medicines Agency Paediatric Strategy Forum for Medicinal Product Development of checkpoint inhibitors for use in combination therapy in paediatric patients","volume":"127","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115230_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2020.04.038","article-title":"Paediatric Strategy Forum for Medicinal Product Development for Acute Myeloid Leukaemia in Children and Adolescents","volume":"136","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115230_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2020.08.014","article-title":"Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","volume":"139","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115230_bib6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2021.08.022","article-title":"Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration","volume":"157","author":"Pearson","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115230_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2021.10.016","article-title":"Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","volume":"160","author":"Pearson","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115230_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2022.06.008","article-title":"Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","volume":"173","author":"Pearson","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115230_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2022.09.036","article-title":"Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","volume":"177","author":"Pearson","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115230_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112950","volume":"190","author":"Pearson","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115230_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114145","article-title":"Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3\u03b2 inhibitors in children and adolescents with cancer","volume":"207","author":"Pearson","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115230_bib12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejca.2014.10.029","article-title":"Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer","volume":"51","author":"Vassal","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115230_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejca.2022.01.033","article-title":"ACCELERATE - Five years accelerating cancer drug development for children and adolescents","volume":"166","author":"Pearson","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.115230_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ctrv.2011.06.007","article-title":"Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology","volume":"38","author":"Jansen","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2025.115230_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(06)70615-5","article-title":"Diffuse brainstem glioma in children: critical review of clinical trials","volume":"7","author":"Hargrave","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000529099","article-title":"Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas","volume":"58","author":"Dalle Ore","year":"2023","journal-title":"Pedia Neurosurg"},{"key":"10.1016\/j.ejca.2025.115230_bib17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/CCO.0000000000000577","article-title":"Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets","volume":"31","author":"Aziz-Bose","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00401-014-1307-x","article-title":"Subventricular spread of diffuse intrinsic pontine glioma","volume":"128","author":"Caretti","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2025.115230_bib19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/neuonc\/noad161","article-title":"Diffuse midline glioma invasion and metastasis rely on cell-autonomous signaling","volume":"26","author":"Bruschi","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib20","series-title":"Diffuse Intrinsic Pontine Glioma","author":"Pellot","year":"2023"},{"key":"10.1016\/j.ejca.2025.115230_bib21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2025.115230_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ng.1102","article-title":"Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas","volume":"44","author":"Wu","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2025.115230_bib23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","article-title":"K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas","volume":"124","author":"Khuong-Quang","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2025.115230_bib24","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00401-018-1826-y","article-title":"cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma\/anaplastic astrocytoma, IDH-mutant","volume":"135","author":"Louis","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2025.115230_bib25","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib26","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00401-020-02142-w","article-title":"Histone H3 wild-type DIPG\/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation","volume":"139","author":"Castel","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2025.115230_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccell.2023.11.002","article-title":"A road map for the treatment of pediatric diffuse midline glioma","volume":"42","author":"Koschmann","year":"2024","journal-title":"Cancer Cell"},{"issue":"ement_2","key":"10.1016\/j.ejca.2025.115230_bib28","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1093\/neuonc\/noad144","article-title":"A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered","volume":"26","author":"Jackson","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib29","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1158\/2159-8290.CD-23-0131","article-title":"Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways","volume":"13","author":"Venneti","year":"2023","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ejca.2025.115230_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(23)00070-0","article-title":"Access to new drugs in paediatric oncology: can we learn from the ongoing ONC201 saga?","volume":"24","author":"Andre","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115230_bib31","article-title":"Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma","volume":"3","author":"Duchatel","year":"2021","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ejca.2025.115230_bib32","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2025.115230_bib33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2025.115230_bib34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ng.2925","article-title":"Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma","volume":"46","author":"Taylor","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2025.115230_bib35","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","article-title":"Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas","volume":"37","author":"Ryall","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2025.115230_bib36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/neuonc\/noaa251","article-title":"A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR","volume":"23","author":"Sievers","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib37","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1200\/JCO.2011.35.5677","article-title":"Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma","volume":"29","author":"Paugh","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2025.115230_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170329","article-title":"PI3K\/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma","volume":"134","author":"Duchatel","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2025.115230_bib39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3171\/2023.7.PEDS22462","article-title":"Survival and neurological outcomes after stereotactic biopsy of diffuse intrinsic pontine glioma: a systematic review","volume":"32","author":"Dalmage","year":"2023","journal-title":"J Neurosurg Pedia"},{"key":"10.1016\/j.ejca.2025.115230_bib40","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00381-023-06208-4","article-title":"Biopsy of diffuse midline glioma is safe and impacts targeted therapy: a systematic review and meta-analysis","volume":"40","author":"Fu","year":"2024","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.ejca.2025.115230_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.wneu.2024.06.163","article-title":"Safety and Technical Efficacy of Pediatric Brainstem Biopsies: An Updated Meta-Analysis of 1000+\u202fChildren","author":"Sheikh","year":"2024","journal-title":"World Neurosurg"},{"key":"10.1016\/j.ejca.2025.115230_bib42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijrobp.2018.12.043","article-title":"A Phase 1\/2 Trial of Reirradiation for Diffuse Intrinsic Pontine Glioma","volume":"104","author":"Amsbaugh","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2025.115230_bib43","first-page":"68","article-title":"Reirradiation practices for children with diffuse intrinsic pontine glioma","volume":"8","author":"Cacciotti","year":"2020","journal-title":"Neurooncol Pr"},{"key":"10.1016\/j.ejca.2025.115230_bib44","unstructured":"Mueller., S., Virtual survey of neuro-oncologists in North America and Europe with expertise in DMG. April 2024."},{"key":"10.1016\/j.ejca.2025.115230_bib45","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ccell.2019.03.014","article-title":"Yet al. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality","volume":"35","author":"Ishizawa","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2025.115230_bib46","doi-asserted-by":"crossref","first-page":"74380","DOI":"10.18632\/oncotarget.11814","article-title":"Discovery and clinical introduction of first-in-class imipridone ONC201","volume":"7","author":"Allen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2025.115230_bib47","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1158\/1078-0432.CCR-22-0803","article-title":"Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003","volume":"28","author":"Kline","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115230_bib48","first-page":"JCO2400709","article-title":"Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201","author":"Hansford","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib49","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/neuonc\/noaa188","article-title":"Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors","volume":"23","author":"He","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib50","unstructured":"Maranto C., Prabhu V. (Chimerix) AACR 2023."},{"key":"10.1016\/j.ejca.2025.115230_bib51","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00401-023-02640-7","article-title":"Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations","volume":"146","author":"Roberts","year":"2023","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2025.115230_bib52","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1158\/0008-5472.CAN-23-0186","article-title":"ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma","volume":"83","author":"Jackson","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.115230_bib54","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2025.115230_bib56","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s42003-019-0420-8","article-title":"ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma","volume":"2","author":"Carvalho","year":"2019","journal-title":"Commun Biol"},{"key":"10.1016\/j.ejca.2025.115230_bib57","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2023.03.007","article-title":"Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities","volume":"41","author":"Sun","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2025.115230_bib58","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.2936","article-title":"Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations","volume":"46","author":"Buczkowicz","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2025.115230_bib59","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma","volume":"46","author":"Wu","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2025.115230_bib60","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/ng.2950","article-title":"Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma","volume":"46","author":"Fontebasso","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2025.115230_bib61","article-title":"BMP2 and BMP7 cooperate with H3.3K27M to promote quiescence and invasiveness in pediatric diffuse midline gliomas","volume":"12","author":"Huched\u00e9","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.ejca.2025.115230_bib62","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1158\/2159-8290.CD-20-1201","article-title":"Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma","volume":"12","author":"Carvalho","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2025.115230_bib63","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170329","article-title":"PI3K\/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma","volume":"134","author":"Duchatel","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2025.115230_bib64","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1158\/0008-5472.CAN-18-3521","article-title":"Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas","volume":"79","author":"Koncar","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.115230_bib65","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/2159-8290.CD-20-0930","article-title":"DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition","volume":"12","author":"Izquierdo","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2025.115230_bib66","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO.2009.25.5463","article-title":"Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets","volume":"28","author":"Zarghooni","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib67","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1126\/science.aao4750","article-title":"Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq","volume":"360","author":"Filbin","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejca.2025.115230_bib69","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00401-020-02155-5","article-title":"Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition","volume":"139","author":"Mondal","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2025.115230_bib70","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41467-022-28198-8","article-title":"PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation","volume":"13","author":"Khadka","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2025.115230_bib71","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1038\/s41467-019-11732-6","article-title":"PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma","volume":"10","author":"Fons","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2025.115230_bib72","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1158\/1541-7786.MCR-19-0507","article-title":"Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib","volume":"18","author":"Wang","year":"2020","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ejca.2025.115230_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1167082","article-title":"Evaluating preclinical evidence for clinical translation in childhood brain tumours: Guidelines from the CONNECT, PNOC, and ITCC brain networks","volume":"13","author":"Jones","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib74","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41467-021-20896-z","article-title":"Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas","volume":"12","author":"Khan","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2025.115230_bib75","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s43018-022-00348-3","article-title":"Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome","volume":"3","author":"Golbourn","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ejca.2025.115230_bib76","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/neuonc\/noz140","article-title":"Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas","volume":"22","author":"Shen","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib77","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2025.115230_bib78","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"e t al. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib79","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41467-019-10043-0","article-title":"The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models","volume":"10","author":"Mart\u00ednez-V\u00e9lez","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2025.115230_bib80","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40478-019-0714-6","article-title":"Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models","volume":"7","author":"Martinez-Velez","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.ejca.2025.115230_bib81","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma","volume":"386","author":"G\u00e1llego P\u00e9rez-Larraya","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115230_bib82","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.ccell.2023.09.001","article-title":"TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory","volume":"41","author":"Ausejo-Mauleon","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2025.115230_bib83","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/CCO.0000000000000995","article-title":"Promises of oncolytic viral therapy for adult and children with brain glioma","volume":"35","author":"Pati\u00f1o-Garc\u00eda","year":"2023","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2025.115230_bib84","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.trecan.2023.07.007","article-title":"CAR T cell therapies for diffuse midline glioma","volume":"9","author":"Thomas","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejca.2025.115230_bib85","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","article-title":"Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+\u202fdiffuse midline gliomas","volume":"24","author":"Mount","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.115230_bib86","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejca.2025.115230_bib87","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-024-08452-3","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+\u202fdiffuse midline gliomas","author":"Monje","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2025.115230_bib88","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.115230_bib89","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2025.115230_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/nrc3811","article-title":"Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma","volume":"14","author":"Jones","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2025.115230_bib91","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1158\/2159-8290.CD-21-1492","article-title":"Epigenome Programming by H3.3K27M Mutation Creates a Dependence of Pediatric Glioma on SMARCA4","volume":"12","author":"Mo","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2025.115230_bib92","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41589-021-00819-1","article-title":"Fighting PRC1 via the RING","volume":"17","author":"Plotnik","year":"2021","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.ejca.2025.115230_bib93","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40478-022-01336-5","article-title":"Ret al. A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis","volume":"10","author":"Dhar","year":"2022","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.ejca.2025.115230_bib94","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.115230_bib95","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/neuonc\/noad141","article-title":"Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047)","volume":"25","author":"Monje","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib96","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/15384101.2018.1469872","article-title":"Targeting of BMI-1 with PTC-209 inhibits glioblastoma development","volume":"17","author":"Kong","year":"2018","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejca.2025.115230_bib97","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.3390\/cells10113252","article-title":"LSD1: Expanding Functions in Stem Cells and Differentiation","volume":"10","author":"Martinez-Gamero","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejca.2025.115230_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108994","article-title":"Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG","volume":"35","author":"Ehteda","year":"2021","journal-title":"Cell Rep"},{"issue":"146","key":"10.1016\/j.ejca.2025.115230_bib100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2011.06.014","article-title":"Mosaic analysis with double markers reveals tumor cell of origin in glioma","volume":"22","author":"Liu","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2025.115230_bib101","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41586-024-07525-7","article-title":"Myelin plasticity in the ventral tegmental area is required for opioid reward","volume":"630","author":"Yal\u00e7\u0131n","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2025.115230_bib102","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41586-023-06678-1","article-title":"Glioma synapses recruit mechanisms of adaptive plasticity","volume":"623","author":"Taylor","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2025.115230_bib103","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3171\/2016.1.JNS151591","article-title":"Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies","volume":"126","author":"Jahangiri","year":"2017","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejca.2025.115230_bib104","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10147-020-01853-0","article-title":"Clinical experience of convection-enhanced delivery (CED) of carboplatin and sodium valproate into the pons for the treatment of diffuse intrinsic pontine glioma (DIPG) in children and young adults after radiotherapy","volume":"26","author":"Szychot","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib105","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/neuonc\/noad105","article-title":"PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma","volume":"25","author":"Mueller","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib106","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(18)30322-X","article-title":"Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial","volume":"19","author":"Souweidane","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib107","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3171\/2020.11.PEDS20571","article-title":"Evaluation of a patient-specific algorithm for predicting distribution for convection-enhanced drug delivery into the brainstem of patients with diffuse intrinsic pontine glioma","volume":"28","author":"Wembacher-Schroeder","year":"2021","journal-title":"J Neurosurg Pedia"},{"key":"10.1016\/j.ejca.2025.115230_bib108","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3171\/2020.6.PEDS20280","article-title":"Repeat convection-enhanced delivery for diffuse intrinsic pontine glioma","volume":"26","author":"Bander","year":"2020","journal-title":"J Neurosurg Pedia"},{"key":"10.1016\/j.ejca.2025.115230_bib109","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/neuonc\/nor051","article-title":"Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump","volume":"13","author":"Sonabend","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib110","doi-asserted-by":"crossref","first-page":"11719","DOI":"10.1073\/pnas.0604318103","article-title":"Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption","volume":"103","author":"Kinoshita","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2025.115230_bib111","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41582-020-00418-z","article-title":"Applications of focused ultrasound in the brain: from thermoablation to drug delivery","volume":"17","author":"Meng","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ejca.2025.115230_bib112","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/s41591-024-02969-w","article-title":"A prognostic neural epigenetic signature in high-grade glioma","volume":"30","author":"Drexler","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.115230_bib113","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1038\/s41467-023-39933-0","article-title":"Spatial cellular architecture predicts prognosis in glioblastoma","volume":"14","author":"Zheng","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2025.115230_bib114","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S1470-2045(20)30173-X","article-title":"Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","volume":"21","author":"Erker","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115230_bib115","article-title":"Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","volume":"21","author":"Cooney","year":"2020","journal-title":"Lancet Oncol 2020;21:e330-e336 Errat-- : Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib116","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1200\/JCO.22.02430","article-title":"Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents","volume":"41","author":"Moreno","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib117","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/1078-0432.CCR-17-0764","article-title":"Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE","volume":"24","author":"Alexander","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115230_bib118","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1200\/JCO.23.01084","article-title":"Use of External Control Cohorts in Pediatric Brain Tumor Clinical Trials","volume":"42","author":"Margol","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115230_bib120","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.21568","article-title":"Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study","volume":"6","author":"Berlanga","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2025.115230_bib128","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3171\/2017.6.JNS162398","article-title":"Enhancement of antitumor activity by using 5-ALA-mediated sonodynamic therapy to induce apoptosis in malignant gliomas: significance of high-intensity focused ultrasound on 5-ALA-SDT in a mouse glioma model","volume":"129","author":"Suehiro","year":"2018","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejca.2025.115230_bib129","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/cancers16040740","article-title":"Theranostic Uses of the Heme Pathway in Neuro-Oncology: Protoporphyrin IX (PpIX) and Its Journey from Photodynamic Therapy (PDT) through Photodynamic Diagnosis (PDD) to Sonodynamic Therapy (SDT)","volume":"16","author":"Marcus","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:47:58Z","timestamp":1777265278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925000115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":116,"alternative-id":["S0959804925000115"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115230","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115230"}}